Effective implementation of modern algorithms for determining the HER2 status of breast cancer

Authors

Keywords:

immunohistochemistry, ISH, sequencing, breast cancer, HER2, algorithm

Abstract

Background. HER2 status is considered the cornerstone of highly effective targeted therapy, mainly in carcinomas of the breast and stomach, as well as tumors of other localizations. The complex methodology for determining the amplification and overexpression of HER2 needs analysis and improvement. Objective: to develop an effective algorithm for the implementation of modern guidelines for determining the HER2 status of breast cancer using IHC and FISH based on the analysis of literature sources and our own experience. Methods. In situ fluorescence hybridization was performed with the ZytoLight SPEC ERBB2 CEN 17 Dual Color Probe followed by digital analysis of photographs. Results. The modern approach to determining HER2-status in classical and doubtful cases is shown on the example of our cases (in situ hybridization). The nature of the evolution of recommendations for determining HER2-status is presented, the modern approach of laboratories is given, the prospects of using sequencing for optimization and individualization of the forecast are covered. Conclusions. Immunohistochemical study and in situ hybridization (ISH) are the main methods for determining HER2 status. Detection of mutations in the HER2 gene based on next-generation sequencing (NGS) is becoming increasingly important in clinical practice. The most effective approach to determining HER2 status includes IHC studies, in which fuzzy results (IHС expression of HER2 2+) perform in situ hybridization, with questionable results (ISH groups 2-4) repeat IHC studies with other blocks

References

  1. Dietel M, Ellis IO, Höfler H, Kreipe H, Moch H, Dankof A, Kölble K, Kristiansen G. Com-parison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists. Virchows Archiv. 2007 Jul;451(1):19-25. DOI 10.1007/s00428-007-0424-5
  2. Papouchado BG, Myles J, Lloyd RV, Stoler M, Oliveira AM, Downs-Kelly E, Morey A, Bilous M, Nagle R, Prescott N, Wang L. Silver in situ hy-bridization (SISH) for determination of HER2 gene status in breast carcinoma: comparison with FISH and assessment of interobserver reproducibility. The American journal of surgical pathology. 2010 Jun 1;34(6):767-76. doi: 10.1097/PAS.0b013e3181d96231
  3. Meric-Bernstam F, Johnson AM, Dumbra-va EE, Raghav K, Balaji K, Bhatt M, Murthy RK, Rodon J, Piha-Paul SA. Advances in HER2-targeted therapy: novel agents and opportunities beyond breast and gastric cancer. Clinical Cancer Research. 2019 Apr 1;25(7):2033-41. DOI: 10.1158/1078-0432.CCR-18-2275
  4. Subramanian J, Katta A, Masood A, Vudem DR, Kancha RK. Emergence of ERBB2 mutation as a biomarker and an actionable target in solid cancers. The oncologist. 2019 Dec;24(12):e1303. doi: 10.1634/theoncologist.2018-0845
  5. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitz-gibbons PL, Hanna WM, Langer A, McShane LM. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Archives of pathology & laboratory medicine. 2007 Jan;131(1):18-43. DOI:10.1200/JCO.2006.09.2775
  6. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Ar-chives of Pathology and Laboratory Medicine. 2014 Feb;138(2):241-56. doi: 10.5858/arpa.2013-0953-SA
  7. Wolff AC, Hammond ME, Allison KH, Harvey BE, Mangu PB, Bartlett JM, Bilous M, Ellis IO, Fitzgibbons P, Hanna W, Jenkins RB. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncolo-gy/College of American Pathologists clinical practice guideline focused update. Archives of pathology & laboratory medicine. 2018 Nov;142(11):1364-82. doi: 10.5858/arpa.2018-0902-SA
  8. Sauter G, Lee J, Bartlett JM, Slamon DJ, Press MF. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. Journal of Clinical Oncology. 2009 Mar 10;27(8):1323-33. DOI: 10.1200/JCO.2007.14.8197
  9. Panigrahi MK, Kumar D, Mehta A, Saikia KK. Outcome of HER2 Testing by FISH applying ASCO/CAP 2007 and 2013 guideline in IHC equiv-ocal group of breast cancer: experience at tertiary cancer care centre. South Asian journal of cancer. 2017 Apr;6(02):45-6. https://www.thieme-connect.com/products/ejournals/pdf/10.4103/2278-330X.208841.pdf
  10. Tchrakian N, Flanagan L, Harford J, Gan-non JM, Quinn CM. New ASCO/CAP guideline recommendations for HER2 testing increase the proportion of reflex in situ hybridization tests and of HER2 positive breast cancers. Virchows Archiv. 2016 Feb 1;468(2):207-11. https://doi.org/10.1007/s00428-015-1871-z
  11. Tarantino P, Hamilton E, Tolaney SM, Cor-tes J, Morganti S, Ferraro E, Marra A, Viale G, Tra-pani D, Cardoso F, Penault-Llorca F. HER2-low breast cancer: pathological and clinical landscape. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2020 Jun 10;38(17):1951-62. DOI https://doi.org/10. 1200/JCO.19.02488
  12. AWMF S3 Leitlinie Mammakarzinom (Langversion 4.4 Juni 2021), https://www.awmf.org/uploads/tx_szleitlinien/032-045OLl_S3_Mammakarzinom_2021-07.pdf
  13. Stoss OC, Scheel A, Nagelmeier I, Schild-haus HU, Henkel T, Viale G, Jasani B, Untch M, Rüschoff J. Impact of updated HER2 testing guide-lines in breast cancer—re-evaluation of HERA trial fluorescence in situ hybridization data. Modern Pa-thology. 2015 Dec;28(12):1528-34. DOI https://doi.org/10.1038/modpathol.2015.112
  14. Madison RW, Gupta SV, Elamin YY, Lin DI, Pal SK, Necchi A, Miller VA, Ross JS, Chung JH, Alexander BM, Schrock AB. Urothelial cancer harbours EGFR and HER2 amplifications and exon 20 insertions. BJU international. 2020 May;125(5):739-46. DOI: 10.1111/bju.15006
  15. AACR Project Genie Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer discovery. 2017 Aug 1;7(8):818-31. DOI: 10.1158/2159-8290.CD-17-0151

Downloads

Published

2023-06-26

How to Cite

Shpon`ka , I., Bondarenko , O., & Shynkarenko , T. (2023). Effective implementation of modern algorithms for determining the HER2 status of breast cancer. Морфологія / Morphologia / Morfologìâ, 15(4), 88–95. Retrieved from https://morphology.dma.edu.ua/article/view/282863

Issue

Vol. 15 No. 4 (2021)

Section

Статті

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

 The authors reserve the right to authorship of their work and transfer to the Journal the right to the first publication of this work under the terms of a license Creative commons Attribution 4.0 International (CC BY 4.0), which allows other people to freely distribute the published work with a mandatory reference to the authors of the original work and the first publication of the work in this journal.
        By submitting a manuscript to the editorial office of the Journal ‘Morphologia’ authors agree to transfer the rights to protect and use the manuscript (all supplemental materials, particularly protected objects such as photos, drawings, diagrams, tables, etc.), including the reproduction in the press and distribution via the Internet; translation of the manuscript into any language; export and import of journal copies with the Authors’ article in order to make it available for public. Authors convey the rights mentioned above to the editorial office without any temporal or territorial limitation all over the world. 
        The Authors guarantee that they have the exclusive rights to use the material transferred to editorial office. Editors are not responsible to third parties for contraventions of warranty given by the Authors. The considered rights are transferred to the editorial office since the moment when the current issue is signed for publishing. Reproduction of materials published in the Journal by other individuals and legal entities is possible only with the consent of Editorial office, with the obligatory indication of the full bibliographic reference of the primary publication. The Authors reserve the right to use the published material, its fragments and parts for teaching materials, oral presentations, dissertation thesis prepararion with obligatory bibliographic citation of the original paper. Electron copy of the published article, downloaded from official journal web-site in .pdf format may be put by authors on the official web-site of their institutions, any other official resources with open access.